biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metasta
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
OMP-313M32
Phase 1 · small molecule · Locally Advanced Cancer
OMP-313M32 for Locally Advanced Cancer is a Phase 1 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Internal code 313M32-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mereo BioPharma Group plc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Locally Advanced Cancer
- Status
- terminated
- Trials
- 1